At the recent San Antonio Breast Cancer Symposium, Professor Hyman Muss received the Brinker Award for Scientific Distinction in Clinical Research for his achievements in the field of breast cancer, in particular in senior patients. Among the many contributions of Hyman Muss to the improvement of care of elderly breast cancer patients, one work is of prime importance [1]: In the late 1990s he was able to convince his Cancer and Leukemia Group B (CALGB) colleagues to start a study on adjuvant chemotherapy in elderly breast cancer patients when there was still considerable skepticism about the value of adjuvant chemotherapy for such patients. This negative view was in part related to wrong interpretation of existing data and to the paucity of results in the older population. The CALGB 49907 trial started in 2001 and has clearly shown that polychemotherapy is superior to single-agent therapy, as administered in the study. In retrospective analyses the study also shows that this benefit tends to be limited to the hormone receptor-negative population. But lately we have been told that polychemotherapy is of equal benefit (same proportional advantage) in endocrine responsive and non-responsive populations, according to the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) [2], maybe because of longer use of anthracyclines and/or taxanes, which were not employed in the CALGB study. It would be sad to again go in the wrong direction because of a statistical value which does not take into account the fact that there are two categories of estrogen receptor-positive patients: those with low risk of recurrence (patients with so-called luminal A cancers), who will have no or very limited benefit from chemotherapy, and the others. Thus, as always, one should not forget biology.

The many questions related to adjuvant chemotherapy in elderly breast cancer patients are discussed in this issue of Breast Care, with emphasis on the biology of the patient – in other words on the probability of tolerance and benefit of the treatment in terms of expected survival [3]. But if chemotherapy is still debated in the elderly, what about surgery?
age of 74 and actually population screening up to 74 years is recommended in several European countries. Beyond that age the decision to look for occult breast cancer should be made by the individual patient and her clinician, based on risks and benefits of screening, patient preference, and life expectancy. And one should not forget that 15–18% of older patients may have highly aggressive ‘triple-negative’ tumors (TNBC), even if some emerging studies suggest that older patients with TNBC may have a better outcome when compared with their younger counterparts. The reasons for these differences in prognosis have yet to be fully elucidated, but may be due to age-related biological variations, as suggested by observed differences in the distribution of histological subtypes of TNBC, or perhaps other unknown (biological) factors [9].

References


